---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-070584"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2024-06-07T23:59:59+00:00"
generated_at: "2026-06-01T05:31:24.679247+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology stockholders approve 5.5M share increase to equity plan at June 5 annual meeting

## Summary
- Stockholders approved Amended 2014 Plan, increasing authorized shares by 5.5M to total 29,827,686 shares.
- Troy E. Wilson and Faheem Hasnain elected as Class I directors until 2027 annual meeting.
- Ratification of Ernst & Young as auditor for FY2024 approved (69.6M for, 56.7K against).
- Advisory vote on executive compensation approved with 61.5M for, 5.4M against.
- About 69.8M of 76.2M outstanding shares were represented at the meeting.

## SEC filing metadata
- accession: 0000950170-24-070584
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2024-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017024070584/0000950170-24-070584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017024070584/kura-20240605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-070584
- JSON: https://secwatch.observer/filing/0000950170-24-070584.json
- Plain text: https://secwatch.observer/filing/0000950170-24-070584.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.